

Int'l Appl. No. : PCT/EP00/07768

Int'l Filing Date: August 10, 2000

added herewith. The changes made to the Specification and the Claims by the current amendment, including insertions and [deletions], are shown on attached sheets entitled **VERSION WITH MARKINGS TO SHOW CHANGES MADE**, which follow the signature page of this amendment.

Should there be any questions concerning this application, the Examiner is respectfully invited to contact the undersigned attorney at the telephone appearing below.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.


Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: _____

2/18/03

By: _____



Mark R. Benedict
Registration No. 44,531
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660

O:\DOCS\MXG\MXG-1166.DOC
021502

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

2. (Amended) The RNA molecule of Claim 1, [characterized in that it] which is replication-competent in the target cell.
3. (Amended) The RNA molecule of Claim 1 [or 2], [characterized in that] wherein in the virus genome parts of its coding sequence have been replaced by the at least one foreign gene.
4. (Amended) The RNA molecule of Claim [3] 2, [characterized in that] wherein in the virus genome the sequences of its capsid proteins VP1-VP4 have been replaced by the at least one foreign gene.
5. (Amended) The RNA molecule of Claim [3 or 4] 2, [characterized in that] wherein in the virus genome the sequences of its protease 2A and/or 3C have been [replaced or] modified such that there is no cytotoxicity for the target cell.
6. (Amended) The RNA molecule of [any of claims 3 to 5] Claim 2, [characterized in that] wherein in the virus genome the sequences of its helicase 2C have been replaced by the at least one foreign gene.
7. (Amended) The RNA molecule of [any of claims 3 to 6] Claim 2, [characterized in that] wherein in the virus genome the sequences of its protein 2B have been replaced by the at least one foreign gene.
8. (Cancelled)
9. (Amended) A recombinant, infectious virion which is derived from Cocksackie Virus group B, preferably serotype B3, and whose genome comprises [is] the RNA molecule of [any of Claims 1 to 7] Claim 1.
10. (Amended) The virion of Claim 9, [characterized in that it] which corresponds in its structural proteins to a Cocksackie virus group B, preferably serotype B3.
11. (Cancelled)
12. (Amended) A vector plasmid having at least one DNA sequence which codes for the RNA molecule of [any of Claims 1 to 7] Claim 1 and having a promoter located in front of the DNA sequence.
13. (Amended) A helper construct for complementing the coding sequences replaced in the RNA molecule of [any of Claims 1 to 7] Claim 1.

14. (Amended) The helper construct of Claim 13, [characterized in that it] which is a helper plasmid which codes for at least one of the replaced sequences in a translatable manner.
15. (Amended) The helper construct of Claim 13, [characterized in that it] which is a viral vector which codes for at least one of the replaced sequences in a translatable manner.
16. (Amended) The helper construct of Claim 13, [characterized in that it] which is a helper cell which has been transfected stably with helper DNA coding for at least one of the replaced sequences.
17. (Cancelled)
18. (Cancelled)
19. (Cancelled)
20. (Cancelled)
21. (Amended) A kit, [with] comprising the vector plasmid of Claim [13] 12 and the helper construct of [any of claims] Claim 13 [to 16].
22. (Amended) A DNA molecule having at least one sequence section coding for the RNA molecule of [any of claims 1 to 7] Claim 1.
24. (Cancelled)
25. (Amended) A therapeutic composition [with] comprising the RNA molecule of [any of claims 1 to 7] Claim 1.
27. (Amended) A therapeutic composition with [virions] the virion of Claim 9 [or claim 10].
28. (Amended) A DNA construct which codes for the RNA molecule of [any of Claims 1 to 7] Claim 1 and which persists and transcribes in a target cell but preferably does not replicate in the latter.
29. (Amended) A recombinant virus, preferably adeno- or retrovirus, which codes for the recombinant RNA molecule of [any of Claims 1 to 7] Claim 1 and, after infection, expresses it in a target cell, leading to a cytoplasmic replicon which is produced continuously.
31. (Cancelled)
32. (Cancelled)